Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease ; volume:11 ; number:12 ; year:2019 ; extent:13
EMBO molecular medicine / European Molecular Biology Organization ; 11, Heft 12 (2019) (gesamt 13)
- Urheber
-
Palmqvist, Sebastian
Insel, Philip S.
Stomrud, Erik
Janelidze, Shorena
Zetterberg, Henrik
Brix, Britta
Eichenlaub, Udo
Dage, Jeffrey L.
Chai, Xiyun
Blennow, Kaj
Mattsson-Carlgren, Niklas
Hansson, Oskar
- DOI
-
10.15252/emmm.201911170
- URN
-
urn:nbn:de:101:1-2022072007152458986903
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Palmqvist, Sebastian
- Insel, Philip S.
- Stomrud, Erik
- Janelidze, Shorena
- Zetterberg, Henrik
- Brix, Britta
- Eichenlaub, Udo
- Dage, Jeffrey L.
- Chai, Xiyun
- Blennow, Kaj
- Mattsson-Carlgren, Niklas
- Hansson, Oskar
Ähnliche Objekte (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Fluid biomarkers in Alzheimer’s disease – current concepts
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Fluid biomarkers in Alzheimer’s disease – current concepts
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies